Consent and privacy in pharmacogenetic testing

The clinical use of pharmacogenetic drugs will require that a sample of a patient's DNA be tested before a drug is prescribed. Although pharmacogenetic tests pose fewer risks than genetic tests for disease mutations, they might still reveal personal information that could be used adversely to a patient's interests. Informed consent and privacy of pharmacogenetic test results may be essential in most clinical uses of pharmacogenetic drugs.

[1]  Elizabeth N. Anionwu,et al.  Assessing Genetic Risks: Implications for Health and Social Policy , 1995 .

[2]  H. Humphrey,et al.  Standards for privacy of individually identifiable health information. , 2003, Health care law monthly.

[3]  Alastair Kent,et al.  Promoting Safe and Effective Genetic Testing in the United States. Final Report of the Task Force on Genetic Testing , 2000 .

[4]  J. Kastner.  Orion Sheds New Light on Star and Planet Formation , 2001, Science.

[5]  E. Marshall.  Company Plans to Bank Human DNA Profiles , 2001, Science.

[6]  Rebecca Herold,et al.  Standards for privacy of individually identifiable health information. Office of the Assistant Secretary for Planning and Evaluation, DHHS. Final rule. , 2001, Federal register.

[7]  S. Feetham.  Comments on the Secretary's Advisory Committee on Genetic Testing document: a public consultation on oversight of genetic tests, January 27, 2000, Baltimore, Maryland. , 2000, Nursing outlook.

[8]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[9]  Lori B. Andrews,et al.  Assessing Genetic Risks: Implications for Health and Social Policy , 1994 .

[10]  Holtzman Na,et al.  Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. , 1999, Journal of child and family nursing.

[11]  A. Torres.  The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications. , 1994, Archives of dermatology.